Pfizer reported a quarterly loss Tuesday following a large write-down, denting shares as it confirmed 2026 financial targets ...

Is Pfizer stock a buy at under 9x earnings? Yes. It is.

Pfizer (PFE) stock dips as the company projects a revenue decline for 2026 amid a nearly $1.5B impact attributed to patent cliffs. Read more here.

Pfizer (PFE) delivered earnings and revenue surprises of +16.81% and +4.26%, respectively, for the quarter ended December ...

By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...

Pharmaceutical company’s stock price move diverges from rival Merck as both groups bolster new treatment pipelines ...

The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.

Evan Seigerman, head of healthcare research at BMO Capital Markets, joins 'Money Movers' to discuss Pfizer and Merck's latest ...

“Pfizer appears cheap with a near 7% yield, but capital allocation constraints undermine its investment case. Nearly all of ...

Analysts expect Pfizer’s revenue to decrease approximately 5% to around $16.95 billion, while adjusted earnings per share are projected to fall 9.5% to 57 cents compared to 63 cents in the same period ...

Pfizer posted adjusted earnings of 66 cents per share, beating the 57 cents forecast by analysts, News.Az reports, citing foreign ...

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.